Pharmacy Medical News about Neuralgia, Postherpetic Pregabalin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pregabalin: In the Treatment of Postherpetic Neuralgia
Drugs & Aging, 09/21/09

McKeage K et al. – Pregabalin is the pharmacologically active S–enantiomer of 3–aminomethyl–5–methyl–hexanoic acid. It has a similar pharmacological profile to that of its developmental predecessor gabapentin, but had greater analgesic activity in rodent models of neuropathic pain.

Oral pregabalin 150–600 mg/day, administered in two or three divided doses, was significantly more effective than placebo in relieving pain and improving pain–related sleep interference in four randomized, double–blind, multicentre studies of 4–13 weeks' duration in patients with postherpetic neuralgia (PHN).
Pregabalin achieved a faster onset of pain relief than placebo. The median times to the onset of pain relief with fixed and flexible doses of pregabalin were 1.5 and 3.5 days compared with >4 weeks with placebo.
Pregabalin was generally well tolerated when titrated over 1 week to fixed dosages (maximum 600 mg/day) in clinical trials in mostly elderly PHN patients. Adverse events were usually mild to moderate in severity.

<< Previous
Cediranib: profile of a novel anti-angiogenic agent in patients...

Next >>
Multidrug-Resistant Gram-Positive Infections in Patients With...